Met/SOL
Our team of three experienced medical doctors, with a strong track record of publications in high-impact SCI and SCI-Expanded journals, is embarking on an ambitious research project to investigate the longevity benefits of metformin. Metformin, widely recognized for its efficacy in managing type 2 diabetes, has drawn growing interest for its potential to influence aging and chronic disease pathways. Preclinical and clinical studies suggest that metformin may play a pivotal role in modulating mechanisms associated with aging, opening new avenues for research in longevity science.
Score | |
|---|---|
24h Vol | $8.37 |
Liquidity | $10.5K |
Holders | 2.2K |
Audits | |
Age | 1 year |
FDV | $7.9K |
Market Cap | $7.9K |
| Addresses | |
|---|---|
| Pool | |
| Met |  |
| SOL | |
| Developer |
Met to SOL Converter
Score | |
|---|---|
24h Vol | $8.37 |
Liquidity | $10.5K |
Holders | 2.2K |
Audits | |
Age | 1 year |
FDV | $7.9K |
Market Cap | $7.9K |
About Metformin (Met)
Our team of three experienced medical doctors, with a strong track record of publications in high-impact SCI and SCI-Expanded journals, is embarking on an ambitious research project to investigate the longevity benefits of metformin. Metformin, widely recognized for its efficacy in managing type 2 diabetes, has drawn growing interest for its potential to influence aging and chronic disease pathways. Preclinical and clinical studies suggest that metformin may play a pivotal role in modulating mechanisms associated with aging, opening new avenues for research in longevity science.
Met/SOL Price Stats
The current price of Met (Met/SOL) on Raydium is $0.000007938, the price is up -1.05% in the last 24 hours. Its 24-hour trading volume is reported to be at $8.3696 with a total of 6 transactions. Met/SOL contract address is Gg6misfiQBuYnnMeAdqCYVzeqPySMUeueaL9PrpZdvwZ, with a Fully Diluted Valuation (FDV) of $7,932.98 and a liquidity pool of $10,496.33.
